Drug-induced pyridoxine deficiency

Drug-induced pyridoxine deficiency is an acquired metabolic depletion of vitamin B6 resulting from pharmacologic therapy that interferes with pyridoxine absorption, metabolism, or coenzyme bioavailability It most commonly affects individuals undergoing treatment with medications such as isoniazid, hydralazine, penicillamine, cycloserine, or certain anticonvulsants Pathophysiologically, these therapeutic agents can form inactive complexes with pyridoxal 5'-phosphate, competitively inhibit pyridox...

Drug-induced pyridoxine deficiency is an acquired metabolic depletion of vitamin B6 resulting from pharmacologic therapy that interferes with pyridoxine absorption, metabolism, or coenzyme bioavailability It most commonly affects individuals undergoing treatment with medications such as isoniazid, hydralazine, penicillamine, cycloserine, or certain anticonvulsants

Pathophysiologically, these therapeutic agents can form inactive complexes with pyridoxal 5'-phosphate, competitively inhibit pyridoxal kinase, or accelerate vitamin catabolism, disrupting neurotransmitter and heme synthesis Clinically, the condition predominantly impacts the nervous, integumentary, and hematologic systems, manifesting as symmetrical sensory peripheral neuropathy, microcytic or sideroblastic anemia, glossitis, cheilosis, seborrheic dermatitis, and, in severe cases, encephalopath...

Pathophysiologically, these therapeutic agents can form inactive complexes with pyridoxal 5'-phosphate, competitively inhibit pyridoxal kinase, or accelerate vitamin catabolism, disrupting neurotransmitter and heme synthesis

Clinically, the condition predominantly impacts the nervous, integumentary, and hematologic systems, manifesting as symmetrical sensory peripheral neuropathy, microcytic or sideroblastic anemia, glossitis, cheilosis, seborrheic dermatitis, and, in severe cases, encephalopathy or intractable seizures